Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective increased by equities research analysts at Stifel Nicolaus from $441.00 to $495.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ price target indicates a potential upside of 8.47% from the company’s current price.

Other equities research analysts have also issued research reports about the company. Truist Financial started coverage on Alnylam Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $385.00 price objective for the company. Royal Bank Of Canada upped their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the company an “outperform” rating in a research note on Friday, September 19th. Morgan Stanley increased their price objective on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Scotiabank increased their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the company a “sector outperform” rating in a research report on Friday, August 1st. Finally, Jefferies Financial Group increased their price target on shares of Alnylam Pharmaceuticals from $328.00 to $384.00 and gave the stock a “buy” rating in a research report on Monday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $445.35.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $456.35 on Monday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. Alnylam Pharmaceuticals has a 1 year low of $205.87 and a 1 year high of $484.21. The company has a fifty day moving average of $441.57 and a two-hundred day moving average of $339.95. The company has a market capitalization of $59.82 billion, a PE ratio of -184.76 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same period last year, the business posted ($0.13) EPS. The company’s revenue was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Michael W. Bonney sold 11,250 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the completion of the sale, the director owned 16,804 shares of the company’s stock, valued at $7,561,800. This trade represents a 40.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares of the company’s stock, valued at approximately $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock worth $44,160,261 over the last 90 days. Insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Atlantic Union Bankshares Corp purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at $30,000. SVB Wealth LLC purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $27,000. Bessemer Group Inc. lifted its position in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 69 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth about $37,000. Finally, Ameritas Advisory Services LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $42,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.